Retinal Vein Occlusion Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Retinal Vein Occlusion Treatment Landscape. Click here to read more @ Retinal Vein Occlusion Pipeline Outlook
Key Takeaways from the Retinal Vein Occlusion Pipeline Report
In July 2025, Retina Research Institute LLC announced a clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain. Receive one drop of the topical drops five minutes prior to their regularly scheduled intravitreal injection. Depending on the treatment arm, they will also administer drops on their own at home up to 3 times per day on the day of their procedure.
DelveInsight's Retinal Vein Occlusion Pipeline analysis depicts the space with 15+ active players working to develop 15+ pipeline therapies.
The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Promising Retinal Vein Occlusion Pipeline Therapies include Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.
For further information, refer to the detailed Retinal Vein Occlusion Drugs Launch, Drugs Developmental Activities, and News, click here @ Retinal Vein Occlusion Ongoing Clinical Trial Analysis
Retinal Vein Occlusion Emerging Drugs
KSI-301: Kodiak sciences
The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.
601: Sunshine Guojian Pharmaceutical
601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.
IBE-814: Ripple Therapeutics
IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).
The Retinal Vein Occlusion Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment.
Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion market
Stay informed about the Retinal Vein Occlusion Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Retinal Vein Occlusion Unmet Needs
Retinal Vein Occlusion Companies
Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type
Retinal Vein Occlusion Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Transform your understanding of the Retinal Vein Occlusion Pipeline! See the latest progress in drug development and clinical research @ Retinal Vein Occlusion Market Drivers and Barriers, and Future Perspectives
Scope of the Retinal Vein Occlusion Pipeline Report
Coverage- Global
Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Retinal Vein Occlusion Pipeline Therapies- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.
Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Ophthalmology Research–Access the Full Retinal Vein Occlusion Pipeline Analysis Today! @ Retinal Vein Occlusion Drugs and Companies
Table of Contents
Introduction
Executive Summary
Retinal Vein Occlusion: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
KSI-301: Kodiak sciences
Mid Stage Products (Phase II)
601: Sunshine Guojian Pharmaceutical
Early Stage Products (Phase I)
MHU650: Novartis
Inactive Products
Retinal Vein Occlusion Key Companies
Retinal Vein Occlusion Key Products
Retinal Vein Occlusion- Unmet Needs
Retinal Vein Occlusion- Market Drivers and Barriers
Retinal Vein Occlusion- Future Perspectives and Conclusion
Retinal Vein Occlusion Analyst Views
Retinal Vein Occlusion Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Should You Buy, Hold or Sell Walmart Stock Before Q2 Earnings?
As Walmart Inc. WMT is slated to report second-quarter fiscal 2026 earnings on Aug. 21 before market open, investors face an important decision on whether they should buy the stock now or hold their current positions. With earnings expectations and market conditions in mind, it is crucial to evaluate key factors influencing Walmart's performance and whether the stock offers an attractive entry point ahead of its earnings report. WMT has established a strong position in global retail by leveraging its diversified business model and omnichannel strategy. Backed by steady traffic growth across stores and digital platforms, as well as expanding high-margin businesses like advertising and membership, Walmart is well-positioned to deliver consistent growth. The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $175.5 billion, indicating 3.7% growth from the year-ago reported level. Also, the consensus mark for quarterly earnings has moved up a penny in the past seven days to 73 cents per share, indicating 9% growth from the year-ago quarter's reported figure. Image Source: Zacks Investment Research Walmart has a trailing four-quarter average earnings surprise of 5.3%. In the last reported quarter, the company's bottom line surpassed the Zacks Consensus Estimate by a margin of 7%. What the Zacks Model Predicts About WMT's Q2 Earnings As investors prepare for Walmart's fiscal second-quarter announcement, the question looms regarding earnings beat or miss. Our proven model conclusively predicts that an earnings beat is likely for WMT this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here. You can see the complete list of today's Zacks #1 Rank stocks here. Walmart has an Earnings ESP of +1.26% and a Zacks Rank #2 at present. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. What's Shaping Walmart's Q2 Earnings? WMT continues to strengthen its position as a resilient and growth-oriented retailer, supported by consistent sales momentum across Walmart U.S., Sam's Club, and its international businesses. Comparable sales (comps) trends highlight broad-based demand, particularly in grocery and health & wellness, wherein the company has expanded its market share. With its ability to attract customers across income groups and blend physical stores with digital platforms, Walmart's omnichannel strategy remains a key competitive advantage, driving customer loyalty and traffic growth. The Zacks Consensus Estimate points to a 4% increase in U.S. comps and a 4.9% rise in Sam's Club U.S. comps for the fiscal second quarter. E-commerce is likely to have been a major catalyst in the fiscal second quarter. Walmart is enhancing convenience with faster delivery capabilities, targeting 95% of the U.S. population with three-hour delivery options. Its marketplace expansion, coupled with improvements in last-mile efficiency, continues to build scale and efficiency, reinforcing Walmart's digital edge. These advancements are contributing to stronger profitability and setting the stage for further margin expansion as digital adoption accelerates. High-margin businesses are also playing a greater role in Walmart's outlook. Membership income has grown at a double-digit pace in the fiscal first quarter, with Walmart+ and Sam's Club both benefiting from strong renewal rates and increased penetration of premium tiers. Advertising has become another growth pillar, with Walmart Connect and international platforms such as Flipkart scaling rapidly. These businesses are likely to have diversified the company's revenue streams and provided earnings stability by reducing the reliance on traditional lower-margin retail sales. International markets have added another dimension to Walmart's growth story. Strong performances in China, Flipkart and Walmex in the recent past highlight the company's ability to tap into high-potential regions and diversify geographic risks. Alongside disciplined inventory management and strategic capital returns, Walmart's healthy balance sheet enables it to invest in growth while rewarding shareholders. On its last reported quarter's earnings call, Walmart expected year-over-year sales growth of 3.5% to 4.5% at constant currency in the fiscal second quarter, supported by ongoing momentum in grocery, membership and e-commerce. However, currency headwinds are likely to have reduced reported sales growth by 120 basis points. While tariff-related cost pressures may create variability in quarterly results, Walmart's scale, sourcing flexibility, and diversified profit streams provide it with the tools to manage through this environment effectively. Walmart's Valuation Picture From a valuation standpoint, Walmart stock is currently trading at a premium compared with the Zacks Retail - Supermarkets industry. With a forward 12-month price-to-earnings (P/E) ratio of 36.56, Walmart stands above the industry average of 33.34, suggesting that the stock may be relatively expensive at current levels. When compared with other retail giants, including The Kroger Co. KR, Target Corporation TGT and Ross Stores, Inc. ROST, the company's valuation looks even more stretched. Kroger trades at a forward P/E of 14.11, Target at 13.51 and Ross Stores at 22.66 — all significantly lower than Walmart's valuation multiple. Currently, Walmart has a Value Score of B. WMT's Price Performance Over the past three months, Walmart's stock has gained 5% compared with the industry's growth of 4.2%. In the same period, the Retail-Wholesale sector and the S&P 500 have risen 7.8% and 10.9%, respectively. The company underperformed some key peers, including Target, which has gained 13.3%. Kroger's stock has rallied 2.6%, while Ross Stores has declined 3.1% over the same period. Should WMT Be in Your Portfolio Pre-Q2 Earnings? Walmart's stock is strengthened by its broad retail reach, seamless integration of physical and digital channels, and expanding profit streams from areas such as marketplace services, advertising, and memberships. The company's ability to capture share in essential categories while investing in faster delivery and international growth provides durable competitive advantages. With earnings estimates trending upward, a strong track record of surprises and favorable indicators for another beat, WMT presents a solid buying opportunity before its fiscal second-quarter earnings release, even at a premium valuation. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Target Corporation (TGT): Free Stock Analysis Report Walmart Inc. (WMT): Free Stock Analysis Report The Kroger Co. (KR): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Market Factors: Natural gas setup looks really promising
In this edition of Market Factors we start with why the depressed natural gas sector may turn out to be a huge opportunity. In part two, a prominent strategist is seeing cracks in the megacap market leadership. And the diversion looks at my favourite movie soundtracks. I've been touting the growth story in natural gas while the commodity price hovers near 25-year lows, so I suppose I owe readers an explanation. I not only believe in the story, but also think things are progressing in a way that will be extremely lucrative for investors if the 2026 demand outlook unfolds as predicted. Natural gas production has significantly exceeded demand this year and this successfully smothered the commodity price. The current end of summer inventory levels are close to record highs thanks to year-to-date production increases of over a billion cubic feet per day. On Tuesday, BofA Securities commodity strategist Clifton White wrote that since 2019, Western Canada natural gas demand growth has come almost exclusively from industrial companies and utilities. Demand from these sources has flagged, increasing oversupply conditions. Now for the good news for investors. Historically the only outlets for domestic natural gas production were pipelines flowing to the U.S. and Eastern Canada. Now, however, the LNG Canada facility on the B.C. coast is operational and gives Canadian gas producers access to global markets. Mr. White believes that LNG Canada 'will cause Western Canada inventories to flip from near record highs this fall to near 10-years lows by the end of summer 2026 [and this] … will lead to stronger AECO prices and fewer Canadian exports to the U.S. next year.' For the natural gas sector, business conditions are bad now and forecast to get much better next year. Theoretically, an investor might be able to find a related stock at depressed prices now, and benefit as conditions improve. We should have a few months of research to attempt to uncover this opportunity. The accompanying table using RBC Capital Markets data can provide a guide to further study. Each stock's leverage to gas prices, valuations in terms of enterprise value to debt-adjusted cash flow and recent performance are included. As always, there are risks for investors. Global natural gas demand, operational issues at LNG Canada and excess production are only three potential events that could screw up this potentially profitable trade. It is still worth further study in my opinion. Megacap stocks have dominated markets since 2015 but one strategist now sees cracks in the trend. A shift in the market cycle from a downturn stage into recovery means smaller cap stocks will retake market leadership, according to BofA's Savita Subramanian. Ms. Subramanian grouped the S&P 500 into deciles and noted that the last Nifty Fifty run – significant outperformance by the largest 50 companies – occurred in the late 1990s. Back then, the outperformance lasted six years and the largest companies outperformed the broader benchmark by 71 percentage points. Currently the biggest 50 stocks have outperformed the benchmark by 73 percentage points since 2015. The average balance sheet quality of today's top 50 is well below the late 1990s. Average valuations are near record highs while growth expectations are, despite the substantial growth forecasts for the magnificent seven, unspectacular overall. The switch to a recovery market cycle historically means that economically sensitive, higher beta (market sensitivity), smaller market cap stocks outperform. Ms. Subramanian expects stocks with lower valuations (in terms of forward PE ratios), above median beta, below median market cap and buy-rated at BofA to outperform. Her screen by these factors uncovered United Airlines Holdings Inc., Halliburton Co., Expedia Group Inc. and lululemon athletica Inc. The MakeUseOf site posted their picks for most underrated movie soundtracks and there are some interesting selections. I hadn't thought of The Last American Virgin as having great music but on review the soundtrack looks great. My picks for favourite soundtracks begin with John Hughes movies, notably the Eric Stoltz and Mary Stuart Masterson classic Some Kind of Wonderful. The Flesh for Lulu song I Go Crazy seals it for Some Kind of Wonderful because that song was impossible to find at the time. (The phenomenon of being completely unable to listen to a song you like must be inexplicable to modern generations. Led Zeppelin's Say Hey Woman was another example). Classics like Wizard of Oz and Singin' in the Rain must be mentioned when the soundtrack topic comes up. For the '80s Purple Rain and then in the '90s there's Singles. The High Fidelity soundtrack is quirky and amazing. Donnie Darko, Trainspotting, Grease, Saturday Night Fever are all notable. I just thought of The Commitments for the first time in at least 25 years because of its terrific and timeless music. What are your favourites? Looking for our updates on market movers, analyst actions, stock technicals, insider trades and other daily, weekly and monthly insight? Click here to visit our Inside the Market page. A look at how this week's inflation report has shifted market and economist views for future Bank of Canada rate cuts The latest Reuters polling of equity strategists and portfolio managers finds a bullish bunch when it comes to the TSX - but less so for the S&P 500 Jamie McGeever takes a closer look at how markets and Donald Trump are in a delicate policy dance Reuters' Ron Buosso on why the Ukraine outcome is insignificant for oil markets The data calendar starts with industrial product prices for July on Thursday when economists expect a 0.3 per cent month-over-month increase. Retail sales for June follows the next day and consensus is looking for a 1.5 per cent rise for the headline number and 0.8 per cent jump ex-autos. Bank earnings are the highlight for Canadian investors in the coming week. Bank of Montreal ($2.942 per share expected) and Bank of Nova Scotia ($1.73) report Tuesday. Royal Bank ($3.317) and National Bank ($2.675) post numbers Wednesday. Dollarama ($1.152) also reports next Wednesday. American economic data of importance begins Thursday with S&P Global U.S. Manufacturing PMI (49.7 expected), which provides an early look at August results. The leading index for July (-0.1 per cent month over month) is also out Thursday but that index has been providing deceptively negative results of late. Preliminary durable goods orders for July (-4.0 per cent month over month) will be released next Tuesday. We'll get corporate results from Walmart Inc. ($0.733) on Thursday and the 27th will see earnings reports from Crowdstrike Holdings Inc. ($0.832) and the big one, Nvidia Corp. ($1.005). See our full earnings and economic calendar here
National Post
3 hours ago
- National Post
Energy Vault, Turkey's Astor Enerji Launch Global Strategic Partnership with BESS Deployments Totalling 2 GWh and 1 GW Transformer Procurement from Astor Enerji
The partnership brings together advanced expertise in energy storage, transformers, high-voltage equipment, and energy management software — maximizing project returns (IRR) while reducing time-to-market for critical infrastructure such as AI Data Centers Article content Energy Vault will deliver to Astor Enerji 2 GWh of B-VAULT™ systems for its grid-connected PV projects, combining advanced energy storage technology with Energy Vault's VaultOS™ software platform to optimize dispatch, accelerate execution, and enhance overall project returns Article content Article content Astor Enerji will deliver to Energy Vault over 1 GW of power transformers and high-voltage equipment, enabling global supply chain acceleration under Energy Vault's Asset Vault platform Article content WESTLAKE VILLAGE, Calif. & ISTANBUL — Energy Vault Holdings, Inc. (NYSE: NRGV), a global leader in grid-scale energy storage solutions, and Astor Enerji (BIST: ASTOR), a leading global manufacturer of high-quality power transformers and high-voltage equipment, today announced the signing of a Global Strategic Agreement to strengthen global supply chains for battery energy storage systems (BESS) and accelerate the deployment of large-scale energy storage and grid infrastructure across multiple markets. Article content This global alliance brings together two fast-growing innovators in the power sector, united by a mission to enable power abundance — delivering the cost-effective and reliable clean electricity needed to fuel industrial growth, digital transformation and long-term economic prosperity. The partnership marks the formation of a powerful industrial alliance, aligning complementary strengths to unlock commercial and technological synergies — including supply chain efficiency, advanced system integration and accelerated execution for utility-scale projects. At a time when U.S. transformer wait times have stretched from 50 weeks to as long as 127 weeks, this collaboration directly addresses supply shortages by leveraging Astor Enerji's manufacturing capacity and global supply chain to ensure access to high-quality equipment from sources outside areas of U.S. concern. Article content Under the agreement: Article content Energy Vault will supply B-VAULT™ BESS solutions for Astor Enerji's four grid-connected photovoltaic (PV) projects in Romania, delivering a combined storage capacity of up to 2 gigawatt-hours (GWh). These systems will be integrated with Energy Vault's VaultOS™ energy management system platform for optimal performance and grid stability. Astor Enerji will provide transformers and high-voltage equipment for more than 1 gigawatt (GW) of Energy Vault BESS projects planned in the United States, Australia, and Europe, creating significant supply chain efficiencies across Energy Vault's global portfolio. Article content By combining Energy Vault's portfolio of advanced long- and short-duration energy storage hardware solutions and AI-driven software platform with Astor Enerji's manufacturing scale and global delivery track record, the partnership unlocks operational efficiency, speeds time-to-market and strengthens grid infrastructure in high-growth regions. Article content Energy Vault will source over 1 GW of transformers and high-voltage equipment from Astor to support its BESS projects, which are being developed and operated through Asset Vault — a fully owned subsidiary dedicated to building, owning, and operating energy storage assets in high-growth global markets. Backed by a recently announced $300 million preferred equity investment, Asset Vault underpins Energy Vault's independent power producer (IPP) strategy, enabling long-term revenues through bankable off-take agreements and merchant market participation. Article content 'This partnership is about more than equipment supply — it's about aligning two high-growth companies to solve the most pressing challenges in the energy transition,' said Marco Terruzzin, Chief Revenue Officer, Energy Vault. 'Together, we are building the technology and supply chain capacity to meet surging power demand from AI data centers and the rapid adoption of renewable energy. This is how we deliver power abundance and economic growth on a global scale.' Article content 'Energy Vault's innovative approach to energy storage, combined with their extensive global project pipeline, makes them an ideal partner as we expand our footprint in the rapidly growing battery storage sector,' said Olcay Doğan, Chief Financial Officer, Astor Enerji. 'This agreement builds on our mission to deliver the grid infrastructure needed for a sustainable energy future, and we are excited to create lasting commercial and technological value together.' Article content develops and deploys utility-scale energy storage solutions designed to transform the world's approach to sustainable energy storage. The Company's comprehensive offerings include proprietary gravity-based storage, battery storage, and green hydrogen energy storage technologies. Each storage solution is supported by the Company's hardware technology-agnostic energy management system software and integration platform. Unique to the industry, Energy Vault's innovative technology portfolio delivers customized short-and-long-duration energy storage solutions to help utilities, independent power producers, and large industrial energy users significantly reduce levelized energy costs while maintaining power reliability. Utilizing eco-friendly materials with the ability to integrate waste materials for beneficial reuse, Energy Vault's gravity-based energy storage technology is facilitating the shift to a circular economy while accelerating the global clean energy transition for its customers. Please visit
